Stifel raised the firm’s price target on Elanco (ELAN) to $16 from $15 and keeps a Buy rating on the shares. Revisiting Q1 earnings reports across Animal Health, Dental and Sleep Apnea, the firm says that in Animal Health it continues to believe the best risk/reward resides with Elanco and argues the stock’s growth algorithm “warrants a higher multiple.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
